[go: up one dir, main page]

DE60030173D1 - Neue Indikationen für Mannan-binding Lectin (MBL) zur Behandlung von immungeschwächten Patienten - Google Patents

Neue Indikationen für Mannan-binding Lectin (MBL) zur Behandlung von immungeschwächten Patienten

Info

Publication number
DE60030173D1
DE60030173D1 DE60030173T DE60030173T DE60030173D1 DE 60030173 D1 DE60030173 D1 DE 60030173D1 DE 60030173 T DE60030173 T DE 60030173T DE 60030173 T DE60030173 T DE 60030173T DE 60030173 D1 DE60030173 D1 DE 60030173D1
Authority
DE
Germany
Prior art keywords
treatment
mbl
mannan
prophylaxis
binding lectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60030173T
Other languages
English (en)
Other versions
DE60030173T2 (de
Inventor
Steffen Thiel
Jens Christian Jensenius
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60030173D1 publication Critical patent/DE60030173D1/de
Publication of DE60030173T2 publication Critical patent/DE60030173T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Filtering Materials (AREA)
  • Wrappers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE60030173T 1999-05-14 2000-05-10 Neue Indikationen für Mannan-binding Lectin (MBL) zur Behandlung von immungeschwächten Patienten Expired - Fee Related DE60030173T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK66899 1999-05-14
DKPA199900668 1999-05-14
DK150899 1999-10-20
DKPA199901508 1999-10-20

Publications (2)

Publication Number Publication Date
DE60030173D1 true DE60030173D1 (de) 2006-09-28
DE60030173T2 DE60030173T2 (de) 2007-08-23

Family

ID=26064419

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60009896T Expired - Fee Related DE60009896T2 (de) 1999-05-14 2000-05-10 Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten
DE60030173T Expired - Fee Related DE60030173T2 (de) 1999-05-14 2000-05-10 Neue Indikationen für Mannan-binding Lectin (MBL) zur Behandlung von immungeschwächten Patienten
DE60033147T Expired - Fee Related DE60033147T2 (de) 1999-05-14 2000-05-10 Rekombinantes menschliches mannan-bindendes lektin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60009896T Expired - Fee Related DE60009896T2 (de) 1999-05-14 2000-05-10 Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60033147T Expired - Fee Related DE60033147T2 (de) 1999-05-14 2000-05-10 Rekombinantes menschliches mannan-bindendes lektin

Country Status (15)

Country Link
US (5) US6846649B1 (de)
EP (3) EP1181038B1 (de)
JP (2) JP2002543837A (de)
CN (2) CN1359420A (de)
AT (3) ATE336260T1 (de)
AU (2) AU781135B2 (de)
CA (2) CA2372128A1 (de)
DE (3) DE60009896T2 (de)
DK (3) DK1402897T3 (de)
ES (3) ES2271468T3 (de)
NO (2) NO20015481L (de)
NZ (2) NZ515718A (de)
PT (3) PT1181038E (de)
RU (2) RU2292217C2 (de)
WO (2) WO2000069894A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) * 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
AU781135B2 (en) * 1999-05-14 2005-05-05 Thomas Vorup Jensen Recombinant human mannan-binding lectin
EP1303288A1 (de) * 2000-07-13 2003-04-23 Natimmune A/S Mannan-bindendes lektin (mbl) zur behandlung von infektionen in tnf alphabehandelte individen
EP1186299A1 (de) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht Diagnose, Verbeugung und/oder Behandlung von Atherosklerose, Infectionen und Störungen des Immunsystems
WO2002041913A1 (en) * 2000-11-27 2002-05-30 Jens Christian Jensenius Collectins as adjuvants
US20040192589A1 (en) * 2001-07-23 2004-09-30 Finn Matthiesen Production of high molecular mass lectins
JP4051030B2 (ja) * 2001-08-31 2008-02-20 扶桑薬品工業株式会社 ヒトマンノース結合レクチンの精製方法、ヒトマンノース結合レクチン組成物およびヒトマンノース結合レクチンの医薬用途
EP1335932B1 (de) * 2001-10-19 2005-11-30 Natimmune A/S Isolierung von lectinen
JP2005526084A (ja) * 2002-03-15 2005-09-02 ナットイムネ・アクティーゼルスカブ マンノース結合レクチンを含む医薬組成物
US7211396B2 (en) * 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin
WO2003090774A1 (en) * 2002-04-24 2003-11-06 The Council Of The Queensland Institute Of Medical Research Mannose binding lectin and uses thereof
AU2003246119B2 (en) * 2002-06-28 2008-02-21 Fuso Pharmaceutical Industries, Ltd. Anti-HIV agent
CN1694961A (zh) * 2002-09-10 2005-11-09 内蒂穆恩公司 胶原凝集素－补体激活蛋白嵌合体
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
RU2353399C2 (ru) * 2003-01-17 2009-04-27 Этлон Медикал, Инк. Способ удаления вирусов из крови посредством лектин-аффинного гемодиализа
PT2374819T (pt) 2003-05-12 2017-07-04 Helion Biotech Aps Anticorpos para masp-2
US7135338B2 (en) * 2003-06-11 2006-11-14 Dobeel Corporation Methods for overexpression of high molecular weight form of mannose binding lectin (MBL) and a specific formulation for active treatment for systemic infection with microorganism
DE20317914U1 (de) 2003-11-19 2004-12-30 Weh, Erwin Betätigungsvorrichtung für eine Schnellanschlusskupplung
US7335633B2 (en) 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
JP4884367B2 (ja) * 2004-02-24 2012-02-29 アボット・ヘルスケア・プロダクツ・ベスローテン・フェンノートシャップ 神経疾患を発症する危険性を決定するための方法
EP1730176A2 (de) * 2004-03-09 2006-12-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mvl, ein antivirales protein aus einem cyanobakterium
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP1618887A1 (de) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Beseitigung von Polyolen aus dem Körper
US20090247454A1 (en) * 2004-09-29 2009-10-01 Mellitus, S.L. Method for detecting a predisposition to develop gestational diabetes mellitus and treatment for this disease
DK1833502T3 (da) * 2004-12-23 2011-06-20 Council Scient Ind Res Farmaceutisk sammensætning til behandling af invasiv pulmonal aspergillose
CN101094651B (zh) * 2004-12-30 2011-03-09 多贝尔有限公司 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法
CN101193651A (zh) * 2005-04-11 2008-06-04 内蒂穆恩公司 甘露聚糖结合凝集素(mbl)在治疗与癌症相关的免疫削弱的病症中的用途
US9220831B2 (en) 2005-10-06 2015-12-29 Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
HRP20110622T1 (hr) 2005-12-21 2011-09-30 Pharming Intellectual Property B.V. Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede
WO2007085057A1 (en) * 2006-01-25 2007-08-02 The Council Of The Queensland Institute Of Medical Research A medical protocol
US20070226567A1 (en) * 2006-03-23 2007-09-27 Gorman Kevin W High speed bist utilizing clock multiplication
US20110052428A1 (en) * 2008-01-16 2011-03-03 Superpar Otomotiv Sanayi Ve Ticaret Anonim Sirketi Electric fuel pump for heavy duty engine platforms
WO2009126346A2 (en) * 2008-01-18 2009-10-15 The General Hospital Corporation Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins
US9156037B2 (en) 2009-01-15 2015-10-13 Children's Medical Center Corporation Microfluidic device and uses thereof
WO2011090954A2 (en) 2010-01-19 2011-07-28 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
WO2011100528A2 (en) * 2010-02-12 2011-08-18 Emory University Compositions and uses of lectins
DE102011003478A1 (de) * 2011-02-01 2012-08-02 Cytavis Biopharma Gmbh Antivirales Mittel enthaltend rekombinante Mistellektine
EP3081937B1 (de) 2011-07-18 2019-11-13 President and Fellows of Harvard College Manipulierte moleküle zum targeting von mikroben und verwendungen davon
AU2013225823A1 (en) 2012-02-29 2014-09-18 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
WO2014014788A2 (en) 2012-07-18 2014-01-23 President And Fellows Of Harvard College Modification of surfaces for simulataneous repellency and targeted binding of desired moieties
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
US9988617B2 (en) 2013-05-21 2018-06-05 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
WO2016077067A2 (en) * 2014-10-27 2016-05-19 President And Fellows Of Harvard College Magnetic capture of a target from a fluid
WO2017024114A1 (en) 2015-08-06 2017-02-09 President And Fellows Of Harvard College Improved microbe-binding molecules and uses thereof
CA3024490A1 (en) 2016-05-16 2017-11-23 President And Fellows Of Harvard College Aqueous biomolecule coupling on co2-plasma-activated surfaces
CN107050436B (zh) * 2017-02-27 2020-03-17 新乡医学院 Mbl在制备预防或治疗效应t细胞引发疾病药物中的应用
CN107050427A (zh) * 2017-02-27 2017-08-18 新乡医学院 MBL在制备预防或治疗以Tregs为靶点的疾病药物中的应用
WO2019110706A1 (en) * 2017-12-08 2019-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of developing a sepsis or a systemic inflammatory response syndrome (sirs)
RU2739113C1 (ru) * 2019-10-04 2020-12-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр терапии и профилактической медицины" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТПМ" Минздрава России) Способ определения активности маннан-связывающих лектин-ассоциированных сериновых протеаз в тесте коагуляции фибриногена
WO2023087090A1 (en) * 2021-11-18 2023-05-25 Magellan Therapeutics Inc. Recombinant proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
WO1989001519A1 (en) * 1987-08-20 1989-02-23 Children's Hospital Corporation Human mannose binding protein
US5112952A (en) 1990-09-28 1992-05-12 Pierce Chemical Company Composition and method for isolation and purification of Immunoglobulin M
AU717207B2 (en) 1995-08-17 2000-03-23 Fuso Pharmaceutical Industries, Ltd. Recombinant conglutinin and producing method thereof
DE69836428T2 (de) 1997-08-21 2007-09-27 Takara Bio Inc., Otsu Karzinostatische wirkstoffe
NZ509089A (en) 1998-06-10 2002-10-25 Statens Seruminstitut Affinity chromatography purification for production of mannan-binding lectin
AU781135B2 (en) * 1999-05-14 2005-05-05 Thomas Vorup Jensen Recombinant human mannan-binding lectin

Also Published As

Publication number Publication date
EP1402897A2 (de) 2004-03-31
US7202207B2 (en) 2007-04-10
ATE336260T1 (de) 2006-09-15
DE60033147T2 (de) 2007-12-13
EP1402897A3 (de) 2004-06-30
ATE264111T1 (de) 2004-04-15
DE60009896D1 (de) 2004-05-19
EP1181363A1 (de) 2002-02-27
US6846649B1 (en) 2005-01-25
NO20015481L (no) 2002-01-11
NO20015506D0 (no) 2001-11-09
RU2292217C2 (ru) 2007-01-27
US20030191052A1 (en) 2003-10-09
CN1359420A (zh) 2002-07-17
CA2372128A1 (en) 2000-11-23
DE60009896T2 (de) 2005-04-21
ATE352620T1 (de) 2007-02-15
US6562784B1 (en) 2003-05-13
WO2000070043A1 (en) 2000-11-23
NZ515718A (en) 2004-03-26
WO2000069894A3 (en) 2001-02-08
US7439224B2 (en) 2008-10-21
PT1181363E (pt) 2007-05-31
DE60030173T2 (de) 2007-08-23
EP1181038A2 (de) 2002-02-27
AU4393500A (en) 2000-12-05
AU781135B2 (en) 2005-05-05
NO20015481D0 (no) 2001-11-08
DK1402897T3 (da) 2006-12-27
PT1181038E (pt) 2004-08-31
DK1181363T3 (da) 2007-05-29
EP1402897B1 (de) 2006-08-16
JP2002544286A (ja) 2002-12-24
CN1359298A (zh) 2002-07-17
NO20015506L (no) 2002-01-09
ES2271468T3 (es) 2007-04-16
RU2005125625A (ru) 2007-02-20
ES2281341T3 (es) 2007-10-01
JP2002543837A (ja) 2002-12-24
PT1402897E (pt) 2007-01-31
ES2219336T3 (es) 2004-12-01
EP1181038B1 (de) 2004-04-14
EP1181363B1 (de) 2007-01-24
WO2000069894A2 (en) 2000-11-23
US20040229212A1 (en) 2004-11-18
DE60033147D1 (de) 2007-03-15
DK1181038T3 (da) 2004-08-09
NZ515717A (en) 2004-01-30
AU779404B2 (en) 2005-01-20
AU4393600A (en) 2000-12-05
CA2372435A1 (en) 2000-11-23
US20070197428A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
DE60030173D1 (de) Neue Indikationen für Mannan-binding Lectin (MBL) zur Behandlung von immungeschwächten Patienten
DE60119534D1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
PT721449E (pt) Inibidores da producao da proteina beta-amiloide
EP2769715A3 (de) Verfahren zur Behandlung von Autoimmunkrankheiten und damit zusammenhängende Reagenzien
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
MY106315A (en) Pharmaceutical agents
HUP0103889A2 (hu) Kopolimer-1-rokon polipeptidek alkalmazása molekulatömeg kalibráló standardként és gyógyászati anyagként
ATE91628T1 (de) Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten.
BG105302A (en) Means for improving cognition
DE60025026D1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
PT652900E (pt) Inibidores da trombina
ATE204759T1 (de) Verwendung von hyperforin und hyperforinhaltigen extrakten zur behandlung und prophylaxe von demenzerkrankungen
DE60118769D1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
NZ228068A (en) Brominated or chlorinated allylamines and their pharmaceutical compositions
FR2710844B1 (fr) Composition pour le traitement ou la prévention de l'herpès.
HUP9903688A2 (hu) Olanzapin alkalmazása az autizmus kezelésére szolgáló gyógyszerkészítmény előállítására
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ATE321528T1 (de) Verwendung von dattelkern-extrakt zur minderung der anzeichen der hautalterung
ATE262343T1 (de) Verwendung von gnrh analogen zur behandlung von schizophrenie
ATE312611T1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
PT1355650E (pt) Combinacao de ingredientes activos contendo alfuzosina e apomorfina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee